The Impact of Social Determinants of Health on Meningococcal Vaccination Awareness, Delivery, and Coverage in Adolescents and Young Adults in the United States: A Systematic Review

Masaquel, Catherine; Schley, Katharina; Wright, Katie; Mauskopf, Josephine; Parrish, Ronika; Hewlett, Dial

doi:10.3390/vaccines11020256

Cited by 6 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 57 Additionally, the lack of vaccine equity leads to inequality in access and distribution of vaccines in general, which is even more pronounced in the case of IMD, as this disease primarily affects those from lower socio-economic backgrounds. 58 , 59 Therefore, revision of the countries’ reimbursement strategies related to IMD is strongly recommended. Lastly, further data collection in this region in the post-COVID-19 era is warranted, as the number of IMD cases reported across Europe are progressively increasing after removal of social restriction measures, and this increasing trend in IMD cases will likely to be seen in this region in the near future.…”

Section: Discussionmentioning

confidence: 99%

Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?

Tzanakaki,

Cabrnochová,

Delić

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Invasive meningococcal disease (IMD) is an acute life-threatening infection caused by the gram-negative bacterium, Neisseria meningitidis . Globally, there are approximately half a million cases of IMD each year, with incidence varying across geographical regions. Vaccination has proven to be successful against IMD, as part of controlling outbreaks, and when incorporated into national immunization programs. The South-Eastern Europe Meningococcal Advocacy Group (including representatives from Croatia, the Czech Republic, Greece, Hungary, Poland, Romania, Serbia, Slovenia and Ukraine) was formed in order to discuss the potential challenges of IMD faced in the region. The incidence of IMD across Europe has been relatively low over the past decade; of the countries that came together for the South-Eastern Meningococcal Advocacy Group, the notification rates were lower than the European average for some country. The age distribution of IMD cases was highest in infants and children, and most countries also had a further peak in adolescents and young adults. Across the nine included countries between 2010 and 2020, the largest contributors to IMD were serogroups B and C; however, each individual country had distinct patterns for serogroup distribution. Along with the variations in epidemiology of IMD between the included countries, vaccination policies also differ.

show abstract

Section: Discussionmentioning

confidence: 99%

Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?

Tzanakaki,

Cabrnochová,

Delić

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Health insurance coverage plays a crucial role in determining access to health care services, including vaccines, as do disparities in race/ethnicity, geography, and socioeconomics. A recent systematic literature review assessing the impact of social determinants of health, specifically for meningococcal vaccination, showed a consistent variance in MenACWY and MenB coverage across population subgroups [ 12 ]. ACIP recognizes the importance of considering issues related to health equity and includes this as a domain in the ACIP’s Evidence to Recommendations (EtR) framework [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

The impact of regional disparities on the availability of meningococcal vaccines in the US

Schley,

Jodar,

Presa

et al. 2024

BMC Public Health

Self Cite

View full text Add to dashboard Cite

Background In the United States (US), three types of vaccines are available to prevent invasive meningococcal disease (IMD), a severe and potentially fatal infection: quadrivalent conjugate vaccines against serogroups A, C, W, Y (MenACWY), and monovalent vaccines against serogroup B (MenB) as well as a newly licensed pentavalent vaccine (MenABCWY) protecting against serogroup A, B, C, W, and Y. The CDC’s Advisory Committee on Immunization Practices (ACIP) routinely recommends MenACWY vaccine for all 11- to 12-year-olds with a booster dose at 16 years. MenB vaccination is recommended based on shared clinical decision-making (SCDM) for 16- to 23-year-olds. Recently, the pentavalent meningococcal vaccine (MenABCWY) was recommended by the ACIP. Meningococcal vaccine uptake is suboptimal across the country, particularly among individuals with lower socioeconomic status (SES), despite these recommendations. The objective of the spatial analyses was to assess the relationship between stocking of MenACWY and MenB vaccines, area-level SES, and state-level policies. Methods The number of MenACWY and MenB doses stocked by vaccinators was obtained from IQVIA and the CDC’s Vaccine for Children (VFC) program and compiled into a county-level dataset from 2016 to 2019. SES, as measured using the CDC’s Social Vulnerability Index (SVI), state-level school recommendations, and universal purchasing programs were among the main county-level covariates included to control for factors likely influencing stocking. Data were stratified by public and private market. Bayesian spatial regression models were developed to quantify the variations in rates of stocking and the relative rates of stocking of both vaccines. Results After accounting for county-level characteristics, lower SES counties tended to have fewer doses of MenB relative to MenACWY on both public and private markets. Lower SES counties tended to have more supply of public vs. private doses. Universal purchasing programs had a strong effect on the markets for both vaccines shifting nearly all doses to the public market. School vaccination strategy was key for improving stocking rates. Conclusions Overall, the results show that MenACWY has greater stock relative to MenB across the US. This difference is exacerbated in vulnerable areas without school entry requirements for vaccination and results in inequity of vaccine availability. Beyond state-level policy and SES differences, SCDM recommendations may be a contributing factor, although this was not directly assessed by our model.

show abstract

Etiologies and comorbidities of meningitis deaths in children under 5 years in high-mortality settings: Insights from the CHAMPS Network in the post-pneumococcal vaccine era

Mahtab,

Madewell,

Baillie

et al. 2024

Journal of Infection

View full text Add to dashboard Cite

The Impact of Social Determinants of Health on Meningococcal Vaccination Awareness, Delivery, and Coverage in Adolescents and Young Adults in the United States: A Systematic Review

Cited by 6 publications

References 56 publications

Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?

Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?

The impact of regional disparities on the availability of meningococcal vaccines in the US

Etiologies and comorbidities of meningitis deaths in children under 5 years in high-mortality settings: Insights from the CHAMPS Network in the post-pneumococcal vaccine era

Contact Info

Product

Resources

About